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Microglial phagocytosis of dead or dying neurons can be beneﬁcial by preventing the
release of damaging and/or pro-inﬂammatory intracellular components. However, there
is now evidence that under certain conditions, such as inﬂammation, microglia can also
phagocytose viable neurons, thus executing their death. Such phagocytic cell death may
result from exposure of phosphatidylserine (PS) or other eat-me signals on otherwise viable
neurons as a result of physiological activation or sub-toxic insult, and neuronal phagocytosis
by activated microglia. In this review, we discuss the mechanisms of phagocytic cell death
and its potential roles in Alzheimer’s Disease, Parkinson’s Disease, and Frontotemporal
Dementia.
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INTRODUCTION
Phagocytosis of host cells is generally thought to be secondary to
the target cell dying by some means such as apoptosis (Savill et al.,
2002;Ravichandran,2003).However,phagocytosis can execute cell
death of viable cells, and we shall refer to this form of cell death as
“primary phagocytosis,” with the deﬁning characteristic that inhi-
bition of phagocytosis prevents cell death. Examples of primary
phagocytosis outside the brain include macrophage phagocyto-
sis of “aged” erythrocytes (Föller et al., 2008; Lee et al., 2011)
and activated neutrophils (Lagasse and Weissman, 1994; Jitkaew
et al., 2009; Stowell et al., 2009; Bratton and Henson, 2011). In
C. elegans, primary phagocytosis has been shown to contribute to
programmed cell death of neuronal precursors during develop-
ment (Hoeppner et al., 2001; Reddien et al., 2001), the elimination
of cells subjected to sub-toxic insults (Neukomm et al., 2011) or
simply as a result of phosphatidylserine (PS) exposure on the sur-
face of cells (Darland-Ransom et al., 2008). In this review, we will
brieﬂy discuss the mechanisms of phagocytosis of cells, current
evidence for primary phagocytosis in the central nervous sys-
tem (CNS) and the resulting implications for neurodegenerative
disease.
MECHANISMS OF PHAGOCYTOSIS OF HOST CELLS
The process of phagocytosis is normally initiated by the release
of attractive signals from the target cell (referred to as “come-get-
me” signals) leading to chemotaxis of a nearby macrophage. Upon
reaching the target cell, the macrophage recognizes cell-surface
signals on the target cell (“eat-me” signals), which then induce its
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phosphatidylserine; Tim4, T-cell immunoglobulin- and mucin-domain-containing
molecule-4; TLR, Toll-like receptor; TREM2, triggering receptor expressed by
myeloid cells-2; VR, vitronectin receptor.
uptake. The best characterized “eat-me” signal is the cell-surface
exposure of phosphatidylserine (PS; Fadok et al., 1992; Martin
et al., 1995), although display of proteins such as calreticulin has
also been implicated (Gardai et al., 2005). In healthy cells, PS is
found exclusively on the inner leaﬂet of the plasma membrane,
because the aminophospholipid translocase removes PS from the
outer leaﬂet. However, a second enzyme, the phospholipid scram-
blase, can cause PS exposure by randomizing phospholipid dis-
tribution between the inner and outer leaﬂets. PS exposure may
occur as a result of: (i) apoptosis (by unknown mechanisms), (ii)
necrosis (due to plasma membrane rupture), (iii) calcium eleva-
tion (which stimulates the phospholipid scramblase and inhibits
the aminophospholipid translocase), (iv) ATP depletion (which
inhibits the aminophospholipid translocase), (v) oxidative stress
(which inhibits the aminophospholipid translocase and stimulates
the scramblase), and/or (vi) fusion of intracellular vesicles with the
plasma membrane (Bratton et al., 1997; Gleiss et al., 2002; Tyurina
et al., 2007).
While PS display has generally been regarded as an early sign
of apoptotic cell death, it is now clear that PS exposure can be
reversible and independent of apoptosis (Dias-Barufﬁ et al., 2003;
Mackenzie et al., 2005; Tyurina et al., 2007; Jitkaew et al., 2009;
Neher et al., 2011), and therefore may lead to the phagocytosis
of viable host cells in the presence of macrophages. For exam-
ple, galectin-1 induces PS exposure on the surface of neutrophils,
which is fully reversible when galectin-1 is removed and does not
lead to cell death. However, when macrophages are present at the
time of PS exposure these cells are phagocytosed and thus killed
(Dias-Barufﬁ et al., 2003; Stowell et al., 2009). Whether exposure
of PS by itself is sufﬁcient for recognition and removal is not
entirely clear: PS exposure may be sufﬁcient for some cells (Fadok
et al., 2001), while others may require PS oxidation or other co-
stimulatory signals to induce phagocytosis (Borisenko et al., 2003,
2004). Furthermore, some healthy cells actively protect themselves
from phagocytic removal by displaying signals on their surface,
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which inhibit phagocytosis (“don’t-eat-me”signals, such asCD200
or CD47; see below).
A range of receptors on the macrophage can mediate recog-
nition of PS on target cells, implying redundancy on ﬁrst
glance. However, not all receptors are expressed by a macrophage
at any one time, but rather are dependent on its activation
state, e.g., classically activated/pro-inﬂammatory vs. alternatively
activated/anti-inﬂammatory macrophages. For example, resting
peritoneal mouse macrophages express the PS receptors Tim4 (T-
cell immunoglobulin- and mucin-domain-containing molecule-
4; Kobayashi et al., 2007; Miyanishi et al., 2007), and alterna-
tively activated human monocyte-derived macrophages express
stabilin-1 (Park et al., 2009) and stabilin-2 (Park et al., 2008).
In contrast, inﬂammatory activated (thioglycollate-elicited) peri-
toneal macrophages upregulate the PS-binding protein MFG-E8
(Milk fat globule EGF-like factor 8, also known as lactadherin,
SED1;Hanayama et al., 2002) and theMer receptor tyrosine kinase
(MerTK), which recognizes PS or other eat-me signals through
bridging molecules Gas6, protein S, galectin-3, tubby, and Tulp1
(Scott et al., 2001; Seitz et al., 2007; Shao et al., 2009; Caberoy
et al., 2011). At the same time, activated (thioglycollate-elicited)
macrophages downregulate expression of other phagocytic pro-
teins such as Tim4 (Miyanishi et al., 2007). Interestingly, it there-
fore appears from the literature that resting macrophages express
receptors that bind PS directly (i.e., Tim4, stabilin-1/2), whereas
activated/pro-inﬂammatorymacrophages utilize phagocytic path-
ways that recruit bridging proteins (e.g., MFG-E8, Gas6), which
bind both PS on the target cell and a receptor on the macrophage
[e.g., vitronectin receptor (VR), MerTK].
Microglia are resident brain macrophages, which continu-
ously and actively survey their microenvironment (Nimmerjahn
et al., 2005). Microglia represent a distinct population of tissue
macrophages as they arise at least in part from primitive myeloid
progenitors during early embryonic stages and are thought to
be maintained by self-replication throughout life in the healthy
brain (Ginhoux et al., 2010). However, under speciﬁc conditions,
such as brain injury and inﬂammation, peripheral monocytes
can be recruited to the brain. This occurs for example after
stroke, but whether peripheral monocytes modify the pathology
of chronic neurodegenerative diseases is disputed. In Alzheimer’s
disease (AD) for example, recent evidence indicates that periph-
eral monocytes do not invade the brain, but contribute to removal
of amyloid-β (Aβ) in the perivascular environment (Mildner et al.,
2011). While it is beyond the scope of this review to discuss this
issue in detail, it appears that invading peripheral monocytes may
mediate effects distinct from residentmicroglia (Prinz et al., 2011).
Nevertheless,microglia share a number of similaritieswith periph-
eral macrophages, including their recognition of both exogenous
“non-self” ligands (e.g., lipopolysaccharide, LPS) and endogenous
“self” ligands (such as Aβ, HSP60, and HMGB1) through pattern
recognition receptors (such as Toll-like receptor-2 and -4; Kawai
and Akira, 2010). Recognition of these ligands results in inﬂam-
mation and associated neurodegeneration due to inﬂammatory
activation of microglia, which also renders the microglia highly
phagocytic (Babcock et al., 2006; Boivin et al., 2007; Hanisch and
Kettenmann,2007;Neher et al., 2011;Neniskyte et al., 2011).Other
macrophage populations in the brain, with phenotypes distinct
from microglia, include those associated with the perivascular
space, the circumventricular organs, the choroid plexus, and the
meninges (Ransohoff and Perry, 2009).
Although data on microglia is limited, they appear to express
similar phagocytic receptors and bridging proteins as peripheral
macrophages. For example, primary microglia in culture express
MFG-E8 (Neher et al., 2011) and MerTK (Grommes et al., 2008),
possibly consistent with a partially activated microglial pheno-
type induced by cell-isolation procedures (Streit et al., 1999) as
expression levels of these two proteins are low in homogenates of
the naïve brain (Binder et al., 2008; Fuller and Van Eldik, 2008).
In support of this notion, it has been reported that stimulation of
microgliawith theTLR4 ligandLPS increasesMerTK expression in
culture, and MerTK and its ligand Gas6 are also upregulated after a
demyelinating insult in the brain (Binder et al., 2008). The expres-
sion of PS receptors in resting microglia has not been investigated
in detail, but the mRNA levels of Tim4 appear to be low in brain
homogenates (Miyanishi et al., 2007; Tanaka et al., 2009). Impor-
tantly, in the CNS, surrounding astrocytes may support microglial
phagocytic function by producing bridging proteins such as MFG-
E8 (Boddaert et al., 2007; Cahoy et al., 2008; Kranich et al., 2010)
and protein S (Stitt et al., 1995), thus enabling efﬁcient clearance
of PS-exposing neurons.
A different phagocytic receptor, triggering receptor expressed
by myeloid cells-2 (TREM2), mediates microglial clearance of
debris and apoptotic neurons in vitro after activation by TREM2
ligands expressed on neuronal cells. Accordingly, knockdown of
TREM2 impairs phagocytic function of microglia and increases
the generation of pro-inﬂammatory cytokines in vitro (Takahashi
et al., 2005). The function of TREM2 and its signaling partner
DNAX adaptor protein-12 (DAP12) are essential for CNS immune
homeostasis as loss-of-function mutations cause Nasu–Hakola
disease (also known as polycystic lipomembranous osteodyspla-
sia with sclerosing leukoencephalopathy, PLOSL), which presents
with inﬂammation and neurodegeneration (Neumann and Taka-
hashi, 2007). This supports the idea that microglial phagocytosis
of dead and dying cells (rather than viable cells) can be protec-
tive and anti-inﬂammatory. The only identiﬁed TREM2 agonist
is the endogenous “self” ligand HSP60, which upon binding to
TREM2 strongly stimulatesmicroglial phagocytosis (Stefano et al.,
2009). Interestingly, HSP60 is also a ligand for TLR4, and TLR4
activation by HSP60 can cause microglial activation and inﬂam-
matory neurodegeneration in vitro (Lehnardt et al., 2008). Thus,
TLR4 activation by HSP60 may contribute to the inﬂammation
and neurodegeneration seen in Nasu–Hakola disease, where the
anti-inﬂammatory signaling via HSP60 and TREM2 would be
missing.
Wang and Neumann (2010) identiﬁed Siglec-11 as a microglial
receptor, which binds polysialylated proteins on the surface of
neurons (in particular neuronal cell adhesion molecule, NCAM)
resulting in inhibition of inﬂammation and phagocytosis. Trans-
fection of mouse microglia with human Siglec-11 reduced the
spontaneous phagocytosis of neurites and neuronal cell bodies
occurring in neuronal–microglial co-cultures, and this was depen-
dent on the presence of polysialylated proteins on the surface of
neurons. Thus polysialylation can act as a “don’t-eat-me” signal
for neurons in vitro.
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Several other molecules can downregulate microglial activity.
CD200 and CD47 are both expressed on the surface of neu-
rons, and are known to act as “don’t-eat-me-signals.” The CD200
receptor (OX2) is found on microglia (Wright et al., 2000), and
CD200 suppresses brain inﬂammation in experimental autoim-
mune encephalomyelitis and after facial nerve transection (Hoek
et al., 2000). CD47 expression on cells and myelin sheaths inhibits
phagocytosis by microglia via a CD47 receptor, SIRPα (Gitik et al.,
2011).
Another signaling pathway that has been shown to modulate
microglial activity is the CX3CL1 (fractalkine)/CX3CR1 pathway.
CX3CL1 is expressed by neurons, while its receptor is predomi-
nantly expressed by microglia in the brain (Harrison et al., 1998).
Inﬂammatory microglial activity can be suppressed by the neu-
ronal chemokine CX3CL1 (also known as fractalkine) via the
microglial chemokine receptor CX3CR1 as shown in neuron–
microglia co-cultures (Zujovic et al., 2000) and in CX3CR1-
deﬁcient mice after systemic injection of LPS, in the MPTP model
of Parkinson’s Disease (PD), as well as in a transgenic model
of amyotrophic lateral sclerosis (Cardona et al., 2006). Further-
more, CX3CR1 knockout restricts natural killer cell recruitment
in experimental autoimmune encephalomyelitis thereby wors-
ening disease outcome (Huang et al., 2006). However, in other
circumstances fractalkine/fractalkine receptor knockout has been
shown to improve neuropathology. For example, CX3CR1 deﬁ-
ciency resulted in improved outcome after spinal cord injury
possibly due to enhanced recruitment of bone marrow derived
macrophages, which also displayed reduced release of inﬂam-
matory mediators (Donnelly et al., 2011). Further, it has been
reported that CX3CL1 deﬁcient mice displayed smaller infarcts
(about 30%) 24 h after middle cerebral artery occlusion (MCAo;
Soriano et al., 2002), although the mechanisms of this effect were
not analyzed in this study. However, a different group showed an
even more pronounced reduction of infarct size (more than 50%),
reduced blood brain barrier damage, leukocyte inﬁltration, neu-
ronal death, and levels of IL-1β (Denes et al., 2008) between 1
and 3 days after MCAo. Importantly, a recent study analyzed the
inﬂuence of the fractalkine/fractalkine receptor pathway after per-
manent MCAo (Cipriani et al., 2011). Similar to the two studies
described above, they found reduced infarct size in both CX3CL1
and CX3CR1 knockout mice 24 h after the insult. Interestingly,
icv infusion of recombinant CX3CL1 in rats also reduced infarct
size and this effect persisted for up to 56 days. When analyz-
ing the in vitro responses of wildtype and CX3CL1 knockout
microglia to medium from oxygen–glucose deprived neurons,
the authors found that microglial phagocytic activity was sup-
pressed only in wildtype, but not in CX3CL1 knockout microglia.
In the same experiment, the release of TNF-α was reduced in
CX3CL1 knockout but not in wildtype microglia demonstrat-
ing a changed microglial response resulting from fractalkine
knockout.
Fractalkine is normally displayed on the cell surface of neu-
rons, but its release is induced by stress such as nerve injury
or excitotoxicity, when it may suppress microglial inﬂammation
but can also act as a chemokine for leukocyte inﬁltration as
well as microglial recruitment. Additionally, soluble fractalkine
may also promote microglial phagocytosis of neuronal debris by
stimulating microglial production and release of MFG-E8 (Har-
rison et al., 1998; Cook et al., 2010; Fuhrmann et al., 2010;
Noda et al., 2011) and induces upregulation of microglial inte-
grin β5 expression, which is one of the subunits of the receptor
for MFG-E8, the VR (Leonardi-Essmann et al., 2005). Interpre-
tation of experiments in CX3CL1 or CX3CR1 knockout animals
are therefore difﬁcult as the outcome may be due to any of the
above mechanisms or combinations thereof. However, from the
literature described above, it appears that suppression of leuko-
cyte recruitment and microglial inﬂammation may dominate the
outcome.
EVIDENCE FOR PRIMARY PHAGOCYTOSIS IN THE CNS
Activation of microglial phagocytosis is generally considered
to be beneﬁcial via removal of pathogens or potentially pro-
inﬂammatory debris and apoptotic cells (Neumann et al., 2009).
However, we and others have shown that microglia can also
phagocytose viable synapses and neurons. For example, during
development microglia may be involved in synaptic pruning, i.e.,
elimination of synapses, and mice lacking the fractalkine receptor,
CX3CR1, show higher densities of spines and functional synapses
during early postnatal development, which the authors attrib-
uted to temporarily reduced microglial density (Paolicelli et al.,
2011). Furthermore, microglia kill developing neurons in cere-
bellar organotypic slices leading to an increase in the number
of fully differentiated Purkinje cell clusters (Marín-Teva et al.,
2004). Similarly, two phagocytosis-related proteins, CD11b and
DAP12, appear to mediate developmental neuronal death in the
hippocampus in vivo (Wakselman et al., 2008). In animals with
a loss-of-function mutation in DAP12 as well as by inhibition
of the complement receptor 3 subunit CD11b, neuronal death
was reduced at postnatal day 1 by about 25%. Both in cerebellar
slices and in the hippocampus, this effect appeared to be medi-
ated through the release of reactive oxygen species, although it is
unclear whether phagocytosis is required for this developmental
death. These data are reminiscent of ﬁndings in the nematode,
where knockdown of phagocytic genes was shown to result in
the survival of neuronal precursor cells that would otherwise die
during development (Hoeppner et al., 2001; Reddien et al., 2001)
indicating a potential role for primary phagocytosis of immature
neurons.
Importantly, we and others have found that stressed but viable
cells can reversibly expose PS in vitro (Tyurina et al., 2007; Jitkaew
et al., 2009; Kim et al., 2010; Neher et al., 2011) and therefore
macrophages may potentially phagocytose viable cells. In particu-
lar, we have shown that microglia activated with LPS (a bacterial
TLR4 agonist), lipoteichoic acid (LTA, a bacterial TLR2 agonist),
or nanomolar concentrations of Aβ (an endogenous TLR2/4 ago-
nist) phagocytose viable neurons in vitro (Figure 1). We found
that microglial activation with these ligands greatly increases their
phagocytic activity, and video imaging of the inﬂamed glial-
neuronal cultures showed highly mobile microglia phagocytos-
ing large numbers of neurons appearing morphologically healthy
(Neher et al., 2011).Mechanistically,we showed that inﬂammatory
activated microglia release reactive oxygen and nitrogen species,
which induce reversible PS exposure on neurons and neuronal
phagocytosis by microglia (Neher et al., 2011; Neniskyte et al.,
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FIGURE 1 | Suggested mechanism of primary phagocytosis in
inflammatory neurodegeneration. Inﬂammatory microglial activation with
lipopolysaccharide (LPS), lipoteichoic acid (LTA), or amyloid-β (Aβ) through
Toll-like receptors-2/4 induces expression of inducible nitric oxide synthase
(iNOS) and assembly of the phagocytic NADPH oxidase (PHOX). iNOS and
PHOX produce nitric oxide (NO) and superoxide (O−2 ), respectively, which
react to form low concentrations of peroxynitrite. These sublethal levels of
peroxynitrite (while not causing neuronal death) are sufﬁcient to cause
neuronal exposure of phosphatidylserine (PS), which is recognized by the
bridging protein MFG-E8 (milk fat globule EGF-like factor 8). MFG-E8 also
binds to the microglial vitronectin receptor (the heterodimeric αvβ3/5 integrin),
thereby causing engulfment of the PS-exposing neuron. If phagocytosis is
blocked, however, neurons are able to re-internalize PS, thus evading
phagocytosis and death.
2011). Speciﬁcally, when inﬂammatory activated microglia were
co-cultured with neurons but physically separated by a transwell
membrane, neurons showed increased PS exposure but no signs
of cell death. When microglia were then allowed to interact with
these neurons, the neurons were phagocytosed and thus killed.
However, if the activated microglia were removed from the trans-
well co-culture, the neuronal PS exposure was fully reversed and
neurons remained viable for as long as they were cultured. This
implied that inﬂamed microglia release soluble mediators that
cause reversible PS exposure on neurons. We identiﬁed these sol-
uble mediators to be reactive oxygen or nitrogen species, probably
peroxynitrite, based on the ﬁndings that the reversible PS expo-
sure and neuronal loss in glial-neuronal cultures is prevented by
inhibitors of theNADPHoxidase (PHOX)ornitric oxide synthases
(NOS), or addition of superoxide dismutase or a peroxynitrite
scavenger. Furthermore, addition of 5–10 μM peroxynitrite alone
caused neuronal loss in the presence of microglia, but reversible PS
exposure and no neuronal loss or death in the absence of microglia
(Neher et al., 2011).
We further identiﬁed a pathway consisting of neuronal PS
exposure, recognition of PS by the bridging molecule MFG-E8,
and MFG-E8 binding to the VR to be essential for neuronal
loss. Again, blocking different components of the PS/MFG-E8/VR
pathway (proteins blocking the exposed PS, antibodies to MFG-
E8, VR antagonists) rescued neurons, leaving apparently healthy
cells behind (Neher et al., 2011; Neniskyte et al., 2011; Fricker
et al., 2012). If the neurons had been killed ﬁrst and then eaten,
then blocking phagocytosis would leave dead neurons. Instead,
blocking phagocytosis in LPS or LTA-treated cultures prevented
essentially all neuronal loss and death, leaving neurons with intact
plasma and mitochondrial membrane potentials, and these neu-
rons remained alive for as long as untreated cultures (Neher et al.,
2011).
More recently we have found that LPS-induced neuronal loss is
absent in glial-neuronal cultures from Mfge8 knockout mice, but
can be reconstituted by adding puriﬁed MFG-E8 to these cultures
(Fricker et al., 2012). The absence or presence of MFG-E8 had no
apparent effect on microglial inﬂammation, and this is very strong
evidence that the inﬂammatory neuronal death is mediated by the
MFG-E8 pathway of phagocytosis. Further, we have shown that
LPS (5μg and 1μg, respectively) injection into the striatumof rats
and mice in vivo causes strong microglial inﬂammation and loss
of 20–30% of neurons, which is reduced by approximately 50%
through co-injection of a VR inhibitor and in Mfge8 knockout
mice (Fricker et al., 2012).
Similarly, McArthur et al. (2010) recently reported that a
microglial cell-line (BV2), when activated with LPS or Aβ phago-
cytosed viable neuron-like cells (PC12). Although a rescue of
neurons by blocking phagocytosis was not shown in this study,
these data further support the idea that inﬂammatory activated
microglia may phagocytose stressed but viable neurons, thereby
executing neuronal death. Altogether, this suggests the possibility
that inﬂammatory neuronal loss in human pathologies may be
prevented by inhibitors of speciﬁc phagocytic pathways.
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POTENTIAL ROLES OF PRIMARY PHAGOCYTOSIS IN
NEURODEGENERATIVE DISEASES
Alzheimer’s disease is characterized by extracellular plaques of
which the main constituent is Aβ. These plaques are associated
with inﬂammatory activated microglia, and there is evidence that
inﬂammation may contribute to the disease (Grifﬁn et al., 1998;
Combs, 2009). Some studies have indicated a beneﬁcial role of
microglia in the disease process, which may be due to phagocytic
removal of Aβ, although it is possible that this effect is mostly
mediated by invading (CCR2+) peripheral monocytes rather than
resident microglia (Simard et al., 2006; El Khoury et al., 2007).
However, it has recently becomeclear that these datamayhavebeen
confounded by the fact that many studies investigating monocyte
recruitment to the brain used whole-body irradiation, which may
prompt invasion of peripheral monocytes. By shielding the brain,
a recent study found that peripheral monocytes did not invade the
brain and that amyloid clearance was mediated by perivascular
myeloid cells (Mildner et al., 2011).
In humans, AD is also characterized by extensive loss of neu-
rons and synapses by means that are not entirely clear. In contrast,
in most animal models of AD neuronal loss is limited, restricted
to speciﬁc brain regions and negatively correlated to plaque load.
However, interestingly in these models neuronal loss occurs pre-
dominantly in the hippocampus, the area affected most severely
in the human condition (Calhoun et al., 1998; Fuhrmann et al.,
2010; Rupp et al., 2011).
High concentrations of Aβ (μM) can induce direct toxicity to
neurons, but low concentrations (nM, which may be more rel-
evant to AD) induce neuronal loss via inﬂammatory activation
of glia in vitro (Maezawa et al., 2011). We found that nanomolar
concentrations of Aβ caused microglia to phagocytose viable neu-
rons and synapses in culture, and if we blocked this phagocytosis
then all neuronal loss and death was prevented (Neniskyte et al.,
2011). This suggests the possibility that microglial phagocytosis of
synapses and neurons contributes to AD.
In line with this hypothesis,Aβ can induce PS exposure on neu-
rons (Mohmmad Abdul and Butterﬁeld, 2005), and there appears
to be an increase in PS-exposed neurons in AD and mild cog-
nitive impairment, as evidenced by PS-exposing synaptosomes
isolated from patients’ brains (Bader Lange et al., 2008, 2010). We
have found that the PS-binding bridging protein MFG-E8 and its
VR mediate inﬂammatory neuronal loss by primary phagocytosis
in vitro (Neher et al., 2011; Neniskyte et al., 2011; Fricker et al.,
2012). Levels of MFG-E8 are reduced in the brains of AD mice
and patients with AD (Boddaert et al., 2007; Fuller and Van Eldik,
2008) possibly due to phagocytosis anddegradation,while integrin
β3, a subunit of the MFG-E8 recognizing VR is strongly upregu-
lated on reactive microglia in AD (Akiyama et al., 1991). However,
it has also been reported that MFG-E8 can interact directly with
Aβ (Boddaert et al., 2007), and it therefore remains to be deter-
mined whether in AD MFG-E8 mediates phagocytosis of Aβ or of
PS-exposing synapses and/or neurons.
Microglia have been shown to contribute to neuronal loss in an
Alzheimer’s mouse model (Fuhrmann et al., 2010). Two-photon
imaging of neuronal loss in the brain of living triple transgenic
APP/PS1/tau AD mice revealed an involvement of microglia in
neuron elimination. Microglial number and migration velocity
was increased prior to loss of neurons and knockout of the
microglial chemokine receptor CX3CR1, which is critical for
microglial chemotaxis, prevented this neuron loss (Fuhrmann
et al., 2010). However, testing whether phagocytosis of neurons
in AD is primary or secondary to neuronal death by other means
in vivo is challenging. Primary phagocytosis (unlike apoptosis or
necrosis) leaves no cell corpse to diagnose the cause of death.
Furthermore, most mouse models expressing mutant APP and
presenilins lack signiﬁcant neuronal loss unless they also include
mutant tau, and we currently lack suitable phagocytosis inhibitors
that cross the blood–brain barrier. However, in principle, mouse
models deﬁcient in phagocytic genes could be used to test for
primary phagocytosis.
More support for an involvement of phagocytosis of cells in
AD comes from recent genome wide association studies. These
analyses revealed that variants in a number of phagocytosis-related
genes promote late onset AD, including ApoE, ApoJ (clusterin),
ABCA7, and CR1 (Jun et al., 2010; Morgan, 2011). ApoE geno-
type has the largest effect on AD incidence, and is known to
modulate phagocytosis of apoptotic cells in vitro and in vivo
(Grainger et al., 2004). Clusterin expression is upregulated by
exposure to phosphatidylserine and it facilitates the uptake of
cellular debris through a pathway mediated by the LDL receptor-
related protein (LRP), megalin, and other yet undeﬁned endo-
cytic receptors (Bach et al., 2001; Bartl et al., 2001). Optimal
ligand-induced signaling through LRP requires the presence of
another protein related to increased AD risk, namely ABCA7.
After stimulation, ABCA7 is transported to the cell membrane,
localizes to the phagocytic cup and enhances the clearance of
apoptotic cells in vitro and in vivo (Jehle et al., 2006). Altogether,
accumulating evidence suggests that microglial phagocytosis of
neurons may have a role in AD. Since impaired phagocytosis
of cells can lead to inﬂammation, it remains to be determined
whether phagocytosis may contribute to AD pathology through
primary phagocytosis of viable synapses/neurons or through
inﬂammation resulting from impaired phagocytosis of dying
cells.
Parkinson’s disease is characterized by motor dysfunction,
resulting from progressive loss of neurons, particularly dopamin-
ergic neurons of the pars compacta region of the substantia nigra
(SN). The causes of neuronal loss may include: α-synuclein inclu-
sions (which may be directly toxic to neurons), mitochondrial
dysfunction, and glial inﬂammation (Tansey et al., 2007). A role
for glial inﬂammation is suggested by the ﬁndings of: (i) inﬂamed
glia and pro-inﬂammatory cytokines in the SN of patients and
animal models, (ii) pro-inﬂammatory agents, e.g., LPS, causing
loss of dopaminergic neurons in culture and in vivo, and (iii)
anti-inﬂammatory drugs being protective in patients and animal
models (McGeer et al., 1988; Herrera et al., 2005; Block et al.,
2007; Tansey et al., 2007). We have found that LPS injection into
rodent striatum causes microglial inﬂammation and neuronal loss
reminiscent of the dopaminergic neuronal loss in LPS-induced
PD. Using this model, we found that neuronal loss and death is
reduced in Mfge8 knockout mice or by co-injection of phago-
cytosis inhibitors (Fricker et al., 2012), suggesting that primary
phagocytosis may contribute to inﬂammatory neuronal loss as it
may occur in PD.
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Substantia nigra neurons are black because they contain neu-
romelanin. Neuromelanin granules are found within activated
microglia of the SN in PD patients, suggesting microglial phago-
cytosis of neurons (McGeer et al., 1988; Banati et al., 1998),
even though there is little evidence of neuronal apoptosis in PD
(Banati et al., 1998). Furthermore, addition of human neurome-
lanin causes microglial activation and dopaminergic neuronal
loss in culture and in vivo, and this neuronal loss is prevented
if a microglial phagocytosis receptor (Mac-1/CR3) is genetically
deleted (Zhang et al., 2011b). Thus the neuromelanin-induced
neuronal loss could be due to primary phagocytosis, however
these results were interpreted in terms of a Mac-1 requirement for
phagocytosis of neuromelanin (Zhang et al., 2011b). Interestingly,
Aβ-induced neuronal loss is also dependent on Mac-1 (Zhang
et al., 2011a), suggesting either that Mac-1 is an Aβ receptor or
that neuronal loss is occurring by primary phagocytosis.
Importantly, it has been reported that in the 6-
hydroxydopaminemodel of PDmicroglia become activated before
any signiﬁcant decrease in the number of dopaminergic neu-
rons. Phagocytic microglia are found attached to morphologically
intact neurons with normal chromatin distribution, suggesting
that microglia may engulf pre-apoptotic neurons precluding the
possibility of their recovery (Marinova-Mutafchieva et al., 2009),
in accordance with a role for primary phagocytosis in PD.
Frontotemporal lobar degeneration (FTD) has a strong genetic
component, and one of the major causes is inactivating muta-
tions in the progranulin gene (Baker et al., 2006; Cruts et al.,
2006). Progranulin deﬁciency leads to exaggerated microglial
response after insult as well as to age-dependent accumulation
of activated microglia (Ahmed et al., 2007; Yin et al., 2010a,b).
Importantly, progranulin was recently found to inhibit phagocy-
tosis of apoptotic/PS-exposed cells in culture and in vivo, and itwas
suggested that neuronal loss in FTD was due to primary phago-
cytosis that progranulin normally suppressed (Kao et al., 2011).
Strikingly, polymorphisms in the progranulin gene are also asso-
ciated with AD, PD, and amyotrophic lateral sclerosis (Brouwers
et al., 2007, 2008; Sleegers et al., 2008). Therefore it is possible that
premature neuronal phagocytosis as observed in the FTD model
may also contribute to pathogenesis of other neurodegenerative
diseases.
CONCLUSION
We have recently found that inﬂammatory activated microglia
can execute neuronal death through phagocytosis. This pri-
mary phagocytosis is a potential mechanism for neuronal loss in
neurodegenerative diseases that present with inﬂammation and
microglial activation, and we have reviewed evidence here sugges-
tive of such a mechanism. Primary phagocytosis may have been
overlooked as a form of cell death as it is difﬁcult to assess whether
a neuron was viable prior to its phagocytosis and because the
general assumption has always been that a cell must die before it
is phagocytosed. The only way to determine whether phagocyto-
sis mediates cell death is by comparing neuronal survival in the
presence and absence of phagocytosis. It will be important to test
the contribution of primary phagocytosis to neuronal death using
models of neurodegenerative disease in mice that are deﬁcient in
phagocytic components.
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